Prosecution Insights
Last updated: October 04, 2026

Quidel Corporation

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Analysis

Quidel Corporation manages a portfolio in the Biotechnology & Pharmaceuticals technology area with 5 pending office actions. These actions are distributed across 5 distinct examiners. This indicates a broad distribution of the workload among the assigned staff, which can lead to varied prosecution experiences across the portfolio.

The prosecution efforts span 4 distinct art units, showing technical diversity within the biotechnology sector. NGUYEN, HENRY H is the busiest examiner, responsible for 1 pending office action. This level of activity reflects a balanced prosecution pipeline with 5 total pending actions spread across multiple examiners and 4 art units. For a practitioner, this means that the prosecution strategy must be adaptable to the different standards and tendencies of 4 separate art units. The fact that 5 examiners are involved for 5 actions shows that the company is engaging with a wide range of expertise at the patent office.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

5
Total Pending OAs
2
Non-Final OAs
2
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (40%)
3
Medium (60%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (60%)
Multi-statute (no §101)2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
80% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
20% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NGUYEN, HENRY H 1 63.7% +37.2%
DEVI, SARVAMANGALA 1 65.3% +55.3%
WHITE, DENNIS MICHAEL 1 58.0% +48.6%
TRAN, CHAU NGUYEN BICH 1 31.6% +45.2%
YAMASAKI, ROBERT J 1 67.6% +43.7%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18307749 EXTRACTION REAGENT FOR USE IN AN ASSAY FOR DETECTION OF GROUP A STREPTOCOCCUS DEVI, SARVAMANGALA 9d overdue
18571173 METHOD TO IDENTIFY INDIVIDUALS WITH T CELL IMMUNITY TO SPECIFIC INFECTIOUS AGENTS NGUYEN, HENRY H —

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18307749 EXTRACTION REAGENT FOR USE IN AN ASSAY FOR DETECTION OF GROUP A STREPTOCOCCUS DEVI, SARVAMANGALA 9d overdue
16816009 COMPOSITIONS, KITS, AND METHODS FOR DETECTING AUTOANTIBODIES YAMASAKI, ROBERT J 27d
18571173 METHOD TO IDENTIFY INDIVIDUALS WITH T CELL IMMUNITY TO SPECIFIC INFECTIOUS AGENTS NGUYEN, HENRY H —
17144991 SUBSTRATE WITH CHANNELS FOR CONTROLLED FLUID FLOW IN BIOLOGICAL ASSAY SAMPLING WHITE, DENNIS MICHAEL —
16817010 RESULT DETERMINATION IN AN IMMUNOASSAY BY MEASURING KINETIC SLOPES TRAN, CHAU NGUYEN BICH —

Top Art Units

Art UnitApps
1645 1
1758 1
1677 1
1651 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18571173 METHOD TO IDENTIFY INDIVIDUALS WITH T CELL IMMUNITY TO SPECIFIC INFECTIOUS AGENTS NGUYEN, HENRY H — §103§112 Final Rejection — Pending Dec 15, 2023
18307749 EXTRACTION REAGENT FOR USE IN AN ASSAY FOR DETECTION OF GROUP A STREPTOCOCCUS DEVI, SARVAMANGALA 1645 §103§112 Final Rejection 9d overdue Pending Apr 26, 2023
17144991 SUBSTRATE WITH CHANNELS FOR CONTROLLED FLUID FLOW IN BIOLOGICAL ASSAY SAMPLING WHITE, DENNIS MICHAEL 1758 §103 Non-Final OA — Pending Jan 08, 2021
16817010 RESULT DETERMINATION IN AN IMMUNOASSAY BY MEASURING KINETIC SLOPES TRAN, CHAU NGUYEN BICH 1677 §103 Non-Final OA — Pending Mar 12, 2020
16816009 COMPOSITIONS, KITS, AND METHODS FOR DETECTING AUTOANTIBODIES YAMASAKI, ROBERT J 1651 §103 Non-Final OA 27d Pending Mar 11, 2020

Managing Quidel Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month